Lancaster, PANCT05348564Now EnrollingIRB Ready

Long QT Syndrome Clinical Trial in Lancaster, PA

Access cutting-edge long qt syndrome treatment through this clinical trial at a research site in Lancaster. Study-provided care at no cost to qualified participants.

Sponsored by University of Maryland, Baltimore

Quick Self-Assessment

See if you qualify for this Lancaster location

Preparing your pre-screening questions…

Expert Care in Lancaster

Access long qt syndrome specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related long qt syndrome treatment provided free

Apply for This Lancaster Location

Check if you qualify for this long qt syndrome clinical trial in Lancaster, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Lancaster

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Lancaster site if eligible
  4. 4Begin participation

About This Long QT Syndrome Study in Lancaster

An important aspect of successful genomic medicine implementation is developing effective approaches for screening at-risk family members after probands are identified, also known as cascade screening. Most cascade screening studies conducted to date have been conducted outside the US, and very few studies have used a rigorous approach involving a comparator group or randomized controlled design. A major question in the field is how to most effectively implement cascade screening, given commonly cited communication barriers, while respecting privacy among probands and family members. This study will conduct a randomized controlled trial to assess direct contact of relatives by study team members vs indirect, or proband-initiated, contact. We will assess efficacy of the cascade screening intervention, patient-centered outcomes regarding mental, physical, and psychosocial outcomes in probands and family members, and implementation evaluation outcomes. Individuals who are known to carry the KCNQ1 Met224Thr or APOB Arg3527Gln variant will be eligible to participate. After providing consent and being deemed eligible, individuals will be randomized in a 1:1 manner into the direct or indirect contact of family members arm of the study. The randomization will be stratified by variant to ensure equal representation of each variant in the study arms. Individuals in the indirect arm will be instructed to contact their first-degree family members about the opportunity to be screened. They will be provided with a disease-specific pamphlet and a family letter explaining the cascade screening. In the direct arm, probands will be advised that the study staff will be contacting their family members. They will be instructed to also contact their family members prior to the study team contacting them. Approximately two weeks after this meeting with the proband, the study staff will mail letters to eligible first-degree family members of the probands. If we do not hear back from individual family members, we will follow-up with another letter, telephone call, or home visit. The information contained in the letters will be the same information for both the direct and indirect arms of the study. All interested family members will receive pre-test counseling and free, in-home, saliva-based genetic testing, and post-test counseling.

Sponsor: University of Maryland, Baltimore

Who Can Participate

Inclusion Criteria

KCNQ1 Thr224Met or APOB R3527Q carrier
18 years or older Proband

Exclusion Criteria

None Family Inclusion Criteria:
1st degree relative of a KCNQ1 Thr224Met or APOB Arg3527Gln carrier Family Exclusion Criteria:

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Lancaster?

Yes, this clinical trial (NCT05348564) has an active research site in Lancaster, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Long QT Syndrome Treatment Options in Lancaster, PA

If you're searching for long qt syndrome treatment options in Lancaster, PA, this clinical trial (NCT05348564) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Lancaster research site is actively enrolling participants for this clinical trial. You'll receive care from experienced long qt syndrome specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all long qt syndrome clinical trials near you to find additional studies recruiting in your area.

More Myalgic Encephalomyelitis Trials in Lancaster, PA

See all myalgic encephalomyelitis clinical trials recruiting in Lancaster — not just this study.

Browse Myalgic Encephalomyelitis Trials in Lancaster →

Ready to Join in Lancaster?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Lancaster, PA